AIM ImmunoTech Inc (NYSEAMERICAN:AIM) said Thursday that its drug Ampligen was able to decrease the infectious viral yield of SARS-SoV-2, the virus that causes COVID-19, by 90% in a recent in vitro model.
In conjunction with the Institute for Antiviral Research at Utah State University, the company tested intranasal Ampligen and found that dramatic reduction in viral yield could be achieved at clinically achievable dosage levels.
These results support Ampligen’s goal of developing an intranasal prophylactic approach using Ampligen to prevent the coronavirus, the company said.
READ: AIM ImmunoTech reports swelling cash on hand, coronavirus/cancer advancement of Ampligen in 2Q update
"We are pleased with these results, as they establish Ampligen's bio-activity against SARS-CoV-2 as well as support our decision to test Ampligen in humans as an intranasal prophylaxis and early-onset therapy against COVID-19," CEO Thomas Equels said in a statement.
Ampligen has already been tested on the SARS-CoV-1 (SARS) virus and showed antiviral promise, the company said.
Last month, AIM announced that its planned Phase 1/2a trial of Ampligen with Roswell Park Comprehensive Cancer Center is on track to commence patient enrollment soon. The trial will examine Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19.
AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel